Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05267093

Acupuncture vs Sham Acupuncture for Hand Osteoarthritis

The investigators plan to conduct this multicentered, sham-controlled randomized clinical trial to evaluate the efficacy and safety of acupuncture for clinical symptomatic improvement of hand OA.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences Guang'anmen Hospital

Beijing, China

Location status: Recruiting

Location contact

Hangyu Shi

CONTACT

[email protected]

+8618811735839

About this study

Symptomatic hand osteoarthritis (HOA) is estimated to affect 15.9% of women and 8.2% of men in the general population. Since no therapy can completely cure HOA at present, alternative effective therapies are needed. Acupuncture has been an effective treatment to alleviate pain and improve joint motion for patients with knee osteoarthritis according to a considerable amount of research. It is not surprised that acupuncture is effective in treating HOA in clinical practice considering the similar pathogenesis HOA shared with knee osteoarthritis. However, the research on the effects of acupuncture in patients with HOA is very limited. The present study aims to evaluate the efficacy and safety of acupuncture for HOA.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed as hand OA according to the American College of Rheumatology (ACR) clinical classification criteria
  • History of hand OA for at least 3 months before enrollment and history of taking nonsteroidal anti-inflammatory drugs (NSAIDs) to treat hand OA
  • Aged 18-80 years
  • At least 40 mm in visual analog scale (VAS) on the average pain intensity of the dominant hand over the last 48 hours (patients applying NSAIDs at the screening have to have an increase in pain in the dominant hand of ≥ 20 mm after 1-week washout)
  • Posterior-anterior radiographs of the dominant hand shows Kellgren-Lawrence grade 1, 2, or 3 changes in symptomatic joints
  • Negative results in both rheumatoid factor and anticyclonic citrullinated peptide
  • Able to comply with the study protocol and understand the medical information forms
  • Voluntarily sign the informed consent

Exclusion criteria

  • History or current evidence of secondary OA (due to causes other than a solely degenerative joint disease) or symptomatic OA at additional locations besides the hand(s) requiring treatment, or any painful syndrome of the upper limb which may interfere with evaluation of hand pain;
  • History of inflammatory arthritis (such as rheumatoid arthritis (RA) or psoriatic arthritis), hemochromatosis, metabolic, or neuropathic arthropathies;
  • History of trauma, dislocation or operation to the hand or arm in the previous 3 months;
  • Hand pain and stiffness due to tissue scarring or tendinitis;
  • Skin damage or serious skin disorders in the hands;
  • Intake of antidepressants, anticonvulsants, vascular or narcotics during the 10 days prior to beginning the study;
  • Oral, intramuscular, intra-articular or intravenous corticosteroids, or hyaluronic acid injection within 3 months preceding enrollment;
  • Serious uncontrolled medical conditions such as cancer, uncontrolled cardiovascular disorder, severe hepatic/renal insufficiency or coagulation disorder;
  • Known phobic to acupuncture or received acupuncture treatment within 4 weeks prior to enrollment.

Treatment and study plan

Acupuncture

Procedure

Sterile single-use stainless steel needles (size 0.3 mm × 25 mm) will be utilized. After local skin disinfection with 75% alcohol wipes, acupuncturists will insert needles perpendicularly into the Ashi points to a depth of approximately 2-3 mm; horizontally into the Baxie points toward the wrist to a depth of 5-10 mm; and perpendicularly into Houxi (SI3) and Waiguan (TE5) to a depth of approximately 5-10 mm. The depth of needling will vary based on the participant's body sizes. After insertion, all needles except those in the Ashi points will be manually manipulated to achieve De qi sensations. All the needles will be retained for 30 min and then gently removed. Participants will take acupuncture treatment three times per week for a total of 12 sessions in 4 consecutive weeks.

Sham acupuncture

Procedure

The sham needles with blunt tips (size 0.3 mm × 25 mm) will be used in the control group. Acupuncturists will gently lift and twist the sham needles to simulate the treatment procedure, thus blinding the patients to the intervention. Acupuncturist will firstly sterilize the areas of acupoints, then apply the adhesive pads on the surface of Ashi points, Baxie points, Houxi (SI3) and Waiguan (TE5) and insert the sham needles without penetrating. The duration and frequency of treatment sessions will be the same as in the acupuncture group.

Primary outcomes

  1. The proportion of responders according to the Outcome Measures in Rheumatological Clinical Trials (OMERACT) and Osteoarthritis Research Society International (OARSI) responder criteria.

    Time frame: week 5

    Participants that meet at least one of the following criteria are considered as responders: 1) at least a 50% decrease and change from baseline≥20 in VAS score; 2) at least a 50% decrease and change from baseline≥20 in Australian Canadian Osteoarthritis Hand Index (AUSCAN); 3) at least a 20% decrease and change from baseline≥10 in at least two measurements of VAS score, AUSCAN and global assessment.

Secondary outcomes

  1. The proportion of responders according to the Outcome Measures in Rheumatological Clinical Trials (OMERACT) and Osteoarthritis Research Society International (OARSI) responder criteria.

    Time frame: week 8 and week 16

    Participants that meet at least one of the following criteria are considered as responders: 1) at least a 50% decrease and change from baseline≥20 in VAS score; 2) at least a 50% decrease and change from baseline≥20 in Australian Canadian Osteoarthritis Hand Index (AUSCAN); 3) at least a 20% decrease and change from baseline≥10 in at least two measurements of VAS score, AUSCAN and global assessment.

  2. Change in average overall finger joints pain intensity in the dominant hand over the past 48h from baseline.

    Time frame: week 5, week 8 and week 16

    Pain intensity will be measured using a 0-100 VAS, with 0 indicating no pain and 100 indicating maximal pain.

  3. Change in maximal overall finger joints pain intensity in the dominant hand over the past 48h from baseline.

    Time frame: week 5, week 8 and week 16

    Pain intensity will be measured using a 0-100 VAS, with 0 indicating no pain and 100 indicating maximal pain.

  4. The proportion of participants achieving at least a 15-point reduction in average overall finger joints pain intensity in the dominant hand from baseline

    Time frame: week 5, week 8 and week 16

    Pain intensity will be measured using a 0-100 VAS, with 0 indicating no pain and 100 indicating maximal pain.

  5. Change in Australian Canadian Osteoarthritis Hand Index (AUSCAN) total score, and pain, stiffness and physical function subscales from baseline.

    Time frame: week 5, week 8 and week 16

    The AUSCAN index contains a 15-item scale referring to hand pain (5 items), stiffness (1 item), and function (9 items) during the preceding 48 hours, which is valid, reliable and responsive in patients with hand OA. All items are scaled on a 0-100 VAS (0=none to 100= very severe), with higher scores indicating more severe symptoms/function.

  6. Change in Functional Index for HOA (FIHOA) from baseline.

    Time frame: week 5, week 8 and week 16

    The FIHOA is a patient-reported hand function questionnaire, comprising 10 items with a four-point Likert scale, in which 0 represents "possible without difficulty", 1 indicates "possible with slight difficulty", 2 represents "possible with important difficulty" and 3 indicates "impossible".

  7. Change in the number of self-reported painful joints and painful joints at digital pressure from baseline.

    Time frame: week 5, week 8 and week 16

    All finger joints will be reported spontaneously for the presence of pain by the participants, and examined by a trained research nurse for the presence of pain at digital pressure.

  8. Change in the number of swollen joints from baseline.

    Time frame: week 5, week 8 and week 16

    All soft swollen finger joints count (0-30) will be assessed by a trained research nurse at each study visit.

  9. Change in hand grip strength of the fingers from baseline.

    Time frame: week 5, week 8 and week 16

    Hand grip strength of the fingers of the dominant hand will be tested using a hand dynamometer.

  10. Change in pinch strength of the fingers from baseline.

    Time frame: week 5, week 8 and week 16

    Hand pinch strength of the fingers of the dominant hand will be tested using a Jamar digital pinch gauge respectively.

  11. Change in patient global assessment of improvement from baseline.

    Time frame: immediately after the intervention, week 8 and week 16

    The patients will be asked to respond to the question 'Considering all the ways your hand OA affects you, how have you been during the last 48 h?' on a self-administered 0-100 VAS (0, worst possible, to 100, best possible, in 10-point increments).

  12. Change in quality of life assessed by the World Health Organization Quality of Life abbreviated version (WHOQOL-BREF) from baseline.

    Time frame: week 5, week 8 and week 16

    The WHOQOL-BREF is a 26-item self-report questionnaire rated on a 5-point Likert-type scale with four domains of QOL: physical (seven items), psychological (six items), social (three items), and environment (eight items), plus 2 items representing the general QOL. The four domain scores are scaled in a positive direction with higher scores indicating a higher quality of life.

Other outcomes

  1. Participants' expectations for acupuncture at baseline.

    Time frame: baseline

    At baseline, participants in both groups will be asked to answer the following question: "What do you expect from EA treatment to improve your hand OA?"

  2. Blinding assessment

    Time frame: immediately after the intervention

    All participants will be told before allocation that insertion is deeper in group A (traditional acupuncture) and shallower in group B (modern acupuncture). After treatments finished, they will be asked "Do you think you were in group A (traditional acupuncture) in the past weeks?", the answers are "Yes", "No" or "Unclear".

  3. Self-reported consumption of acetaminophen for hand OA.

    Time frame: during weeks 1-4, weeks 5-8 and weeks 9-16

    The proportion of participants using acetaminophen, and the frequency and total dosage of acetaminophen used will be calculated and assessed.

  4. Safety assessment

    Time frame: during weeks 1-4, weeks 5-8 and weeks 9-16

    Any acupuncture-associated adverse event (AE) such as dizziness, palpitations, local hematomas, or infection, and any other AE irrelevant to acupuncture, will be carefully documented.

Study contacts

Contact information is provided by the study sponsor or research team.

Weiming Wang, Ph.D

CONTACT

[email protected]

+8613426424993

Sponsors and collaborators

Lead sponsor

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Other

Registry information

Official study title

Efficacy of Acupuncture for Patients With Hand Osteoarthritis: a Randomized, Sham-controlled Trial

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Mar 4, 2022
Registry last updated
Jul 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.